1Della Bella S, Molteni M, Mascagni B, et al.Cytokine production in scleroderma patients:effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 1997; 15: 135-141.
2Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108:241 - 250.
3Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud' s phenomenon secondary to systemic sclerosis: a multicenter, placebo- controlled, doubleblind study. Arthritis Rheum 1998;41:670.
4Schwartz J, Gonzalez J, Palangio M, et al.Extracorporeal photochemotherapy inprogressive systemic sclerosis: a follow - up study.Int J Dermatol 1997;36:380 - 385.
5Muellegger RR, Hofer A, Salmhofer W, et al. Extended extracorporeal photochemotherapy with extracorporeal administration of 8 -methoxypsoralen in systemic sclerosis. An Austrian single - center study. Photodermatol Photoimmunol Photomed 2000; 16:216 - 223.
6Clements PJ, Furst DE, Wong WK, et al.High- dose versus low- dose D - penicillamine in early diffuse systemic sclerosis: analysis of a two - year, double - blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194 - 1203.
7Shapiro M, Jimenez S, Werth VP, et al.Pemphigus vulgaris induced by D - penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol 2000; 42: 297-299.
8Garcia Porrua C, Gonzalez Gay MA, Bouza P, et al. D- penicillamine - induced crescentic glomerulonephritis in a patient with scleroderma. Nephron 2000; 84:101 - 102.
9Seibold JR, Korn JH, Simms R, et al.Recombinant human relaxin in the treatment of scleroderma. A randomized, doubleblind, placebo- controlled trial. Ann Intern Med 2000; 132:871 - 879.
10Dziadzio M, Denton CP, Smith R, et al.Losartan therapy for Raynaud' s phenomenon and scleroderma: clinical and biochemical findings in a fifteen - week, randomized,parallel- group, controlled trial. Arthritis Rheum 1999 ;42: 2646 - 2655.
